Immatics (NASDAQ:IMTX), a Tübingen, Germany-based clinical-stage biopharmaceutical company developing T cell receptor (TCR)-based immunotherapies for the treatment of solid tumors, on Thursday reported a net loss of $41.6 million for its fourth quarter ended December 31, 2025.
Lexicon Pharmaceuticals (NASDAQ:LXRX) reported fourth-quarter financial results on Thursday that exceeded Wall Street expectations, driven by reduced operating expenses and licensing revenue.
Regenxbio (NASDAQ:RGNX) shares faced pressure Thursday after the biotechnology company reported fourth-quarter financial results that trailed Wall Street expectations on both the top and bottom lines.
MediWound (NASDAQ:MDWD), a biopharmaceutical developer focused on enzymatic therapeutics for tissue repair, reported fourth-quarter losses that were narrower than analysts had anticipated.
Olaplex Holdings (NASDAQ:OLPX) shares declined on Thursday after the company provided a cautious financial outlook for 2026, overshadowing a fourth quarter that saw a modest return to top-line growth.
Bioventus (NASDAQ:BVS) reported a return to profitability for the full year 2025, supported by a strong fourth-quarter performance that saw organic revenue accelerate across its core healing therapies.
John Wiley & Sons (NYSE:WLY) reported third-quarter results on Thursday that underscored the company's ongoing efforts to streamline operations and focus on its high-growth research publishing business.
Victoria’s Secret (NYSE:VSCO) reported fourth-quarter and full-year 2025 results on March 5, 2026, that surpassed both internal guidance and Wall Street estimates.
Burlington Stores (NYSE:BURL) reported a robust fourth-quarter performance that exceeded internal expectations, driven by strong customer traffic and a significant expansion in profit margins.
Myers Industries (NYSE:MYE) reported a 173% surge in fourth-quarter earnings per share, clearing analyst estimates as the company successfully executed its "Focused Transformation" efficiency program.
Evogene (NASDAQ:EVGN) announced a fundamental strategic refocusing alongside its fourth-quarter and full-year 2025 financial results, moving to concentrate its resources on its proprietary ChemPass AI™ tech-engine.
Stratasys (NASDAQ:SSYS) shares fell more than 6% in pre-market trading, Thursday after the company provided a 2026 financial outlook that suggests continued headwinds for the additive manufacturing sector, despite a fourth-quarter earnings performance that beat expectations.
